UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 1016-13
Program Prior Authorization/Notification
Medication Cayston® (aztreonam for inhalation solution)
P&T Approval Date 11/2011, 5/2012, 5/2013, 2/2014, 2/2015, 2/2016, 2/2017, 2/2018, 2/2019,
2/2020, 2/2021, 2/2022, 2/2023, 2/2024, 2/2025
Effective Date 5/1/2025
1. Background:
Cayston (aztreonam solution for inhalation) is a monobactam antibacterial indicated to improve
respiratory symptoms in cystic fibrosis (CF) patients with Pseudomonas aeruginosa. Safety and
effectiveness have not been established in pediatric patients below the age of 7 years, patients with
forced expiratory volume in 1 second (FEV ) < 25% or > 75% predicted, or patients colonized with
1
Burkholderia cepacia.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cayston and
other antibacterial drugs, Cayston should be used only to treat patients with CF known to have
Pseudomonas aeruginosa in the lungs.
Members will be required to meet the coverage criteria below.
2. Coverage Criteriaa:
A. Initial Authorization
1. Cayston will be approved based on both of the following criteria:
a. Diagnosis of cystic fibrosis (CF)
-AND-
b. Lung infection with positive culture demonstrating Pseudomonas aeruginosa infection
Authorization will be issued for 12 months
B. Reauthorization
1. Cayston will be approved based on the following criterion:
a. Documentation of positive clinical response to Cayston therapy
Authorization will be issued for 12 months
a State mandates may apply. Any federal regulatory requirements and the member specific benefit
plan coverage may also impact coverage criteria. Other policies and utilization management
programs may apply.
© 2025 UnitedHealthcare Services, Inc.
1
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization
based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.
Use of automated approval and re-approval processes varies by program and/or therapeutic class.
• Supply limits may be in place.
4. References:
1. Cayston [package insert]. Foster City, CA: Gilead Sciences, Inc.; November 2019.
Program Prior Authorization/Notification - Cayston (aztreonam for inhalation
solution)
Change Control
2/2014 Updated Background. Removed reauthorization criteria and increased
authorization to 60 months.
2/2015 Annual review with no change to coverage criteria. Updated background
and references.
2/2016 Annual review with no changes to clinical content. Changed authorization
period to 12 months and added re-authorization period for 12 months.
2/2017 Annual review. No changes to coverage criteria.
2/2018 Annual review. No changes to coverage criteria.
2/2019 Annual review. No changes to coverage criteria.
2/2020 Annual review. Update to background. No changes to coverage criteria.
2/2021 Annual review. No changes to coverage criteria.
2/2022 Annual review with no changes to coverage criteria.
2/2023 Annual review with no changes to coverage criteria. Added state mandate.
2/2024 Annual review. Updated background. No changes to coverage criteria.
2/2025 Annual review. No changes to coverage criteria.
© 2025 UnitedHealthcare Services, Inc.
2